Docetaxel consolidation therapy following cisplatin, vinorelbine, and concurrent thoracic radiotherapy in patients with unresectable stage III non-small cell lung cancer

Journal of Thoracic Oncology

Volumn 1, Issue 8, 2006, Pages 810-815

  Sekine, Ikuo ^a   Nokihara, Hiroshi ^a   Sumi, Minako ^a   Saijo, Nagahiro ^b   Nishiwaki, Yutaka ^b   Ishikura, Satoshi ^b   Mori, Kiyoshi ^c   Tsukiyama, Iwao ^c   Tamura, Tomohide ^a  

^a NATIONAL CANCER CENTER HOSPITAL   (Japan)

^b NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

^c TOCHIGI CANCER CENTER   (Japan)

Author keywords

Chemoradiotherapy; Consolidation; Docetaxel; Non small cell lung cancer

Indexed keywords

CISPLATIN; DOCETAXEL; NAVELBINE; SEROTONIN 3 ANTAGONIST; STEROID; ANTINEOPLASTIC AGENT; DRUG DERIVATIVE; TAXOID; VINBLASTINE;

ADULT; AGED; ANEMIA; ANOREXIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CONFIDENCE INTERVAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ESOPHAGITIS; FEMALE; HEART MUSCLE ISCHEMIA; HISTOGRAM; HUMAN; HYPERKALEMIA; HYPONATREMIA; ILEUS; INFECTION; INOPERABLE CANCER; LEUKOPENIA; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PATIENT SELECTION; PNEUMONIA; PRIORITY JOURNAL; RADIATION DOSE; RADIATION PNEUMONIA; RADIATION RESPONSE; RANK SUM TEST; SURVIVAL RATE; SURVIVAL TIME; SYNCOPE; THERAPY EFFECT; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING; CLINICAL TRIAL; LUNG TUMOR; MIDDLE AGED; MORTALITY; MULTIMODALITY CANCER THERAPY; RADIATION INJURY;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; RADIATION INJURIES; SURVIVAL RATE; TAXOIDS; VINBLASTINE;

EID: 34248364457     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/01243894-200610000-00009     Document Type: Article

References (16)

1. Vokes EE, Crawford J, Bogart J, et al. Concurrent chemoradiotherapy for unresectable stage III non-small cell lung cancer. Clin Cancer Res 2006;11:5045s-5050s.
2. Auperin A, Le Pechoux C, Pignon JP, et al. Concomitant radio-chemotherapy based on platin compounds in patients with locally advanced non-small cell lung cancer (NSCLC): a meta-analysis of individual data from 1764 patients. Ann Oncol 2006;17:473-483.
3. Fournel P, Robinet G, Thomas P, et al. Randomized phase III trial of sequential chemoradiotherapy compared with concurrent chemoradiotherapy in locally advanced non-small-cell lung cancer: Groupe Lyon-Saint-Etienne d'Oncologie Thoracique-Groupeqqfrancaisqqqq de Pneumo-Cancerologie NPC 95-01 Study. J Clin Oncol 2006;23:5910-5917.
4. Furuse K, Fukuoka M, Kawahara M, et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. J Clin Oncol 1999;17:2692-2699.
5. Curran W, Scott CJ, Langer C, et al. Long-term benefit is observed in a phase III comparison of sequential vs concurrent chemo-radiation for patients with unresected stage III NSCLC: RTOG 9410. Proc Am Soc Clin Oncol 2003;22:621 (abstr 2499).
6. Sekine I, Noda K, Oshita F, et al. Phase I study of cisplatin, vinorelbine, and concurrent thoracic radiotherapy for unresectable stage III non-small cell lung cancer. Cancer Sci 2004;95:691-695.
7. Fossella FV, DeVore R, Kerr RN, et al. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group. J Clin Oncol 2000;18:2354-2362.
8. Shepherd FA, Dancey J, Ramlau R, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 2000;18:2095-2103.
9. Fossella FV, Lee JS, Shin DM, et al. Phase II study of docetaxel for advanced or metastatic platinum-refractory non-small-cell lung cancer. J Clin Oncol 1995;13:645-651.
10. Gandara DR, Chansky K, Albain KS, et al. Consolidation docetaxel after concurrent chemoradiotherapy in stage IIIB non-small-cell lung cancer: phase II Southwest Oncology Group Study S9504. J Clin Oncol 2003;21:2004-2010.
11. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-216.
12. Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials 1989;10:1-10.
13. Armitage P, Berry G, Matthews J. Survival analysis. In Armitage P, Berry G, Matthews J (eds.), Statistical Methods in Medical Research (4th ed.). Oxford: Blackwell Science Ltd, 2002, pp. 568-590.
14. Belani CP, Choy H, Bonomi P, et al. Combined chemoradiotherapy regimens of paclitaxel and carboplatin for locally advanced non-small-cell lung cancer: a randomized phase II locally advanced multi-modality protocol. J Clin Oncol 2006;23:5883-5891.
15. Carter D, Keller A, Tolley R, et al. A randomized phase III trial of combined paclitaxel, carboplatin, and radiation therapy followed by either weekly paclitaxel or observation in patients with stage III nonsmall cell lung cancer. Proc Am Soc Clin Oncol 2006;22:635s (abstr 7076).
16. Mac Manus MP, Hicks RJ, Matthews JP, et al. Metabolic (FDG-PET) response after radical radiotherapy/chemoradiotherapy for non-small cell lung cancer correlates with patterns of failure. Lung Cancer 2006;49:95-108.